JP2017506662A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506662A5
JP2017506662A5 JP2016554571A JP2016554571A JP2017506662A5 JP 2017506662 A5 JP2017506662 A5 JP 2017506662A5 JP 2016554571 A JP2016554571 A JP 2016554571A JP 2016554571 A JP2016554571 A JP 2016554571A JP 2017506662 A5 JP2017506662 A5 JP 2017506662A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
coxsackievirus
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506662A (ja
JP6857498B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/000111 external-priority patent/WO2015127501A1/en
Publication of JP2017506662A publication Critical patent/JP2017506662A/ja
Publication of JP2017506662A5 publication Critical patent/JP2017506662A5/ja
Application granted granted Critical
Publication of JP6857498B2 publication Critical patent/JP6857498B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554571A 2014-02-27 2015-02-27 癌を処置するための併用方法 Expired - Fee Related JP6857498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014900647A AU2014900647A0 (en) 2014-02-27 Combination method for treatment of cancer
AU2014900647 2014-02-27
PCT/AU2015/000111 WO2015127501A1 (en) 2014-02-27 2015-02-27 Combination method for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001547A Division JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Publications (3)

Publication Number Publication Date
JP2017506662A JP2017506662A (ja) 2017-03-09
JP2017506662A5 true JP2017506662A5 (cg-RX-API-DMAC7.html) 2020-05-21
JP6857498B2 JP6857498B2 (ja) 2021-04-14

Family

ID=54008051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554571A Expired - Fee Related JP6857498B2 (ja) 2014-02-27 2015-02-27 癌を処置するための併用方法
JP2021001547A Pending JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021001547A Pending JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Country Status (9)

Country Link
US (3) US20170000832A1 (cg-RX-API-DMAC7.html)
EP (2) EP3110443A4 (cg-RX-API-DMAC7.html)
JP (2) JP6857498B2 (cg-RX-API-DMAC7.html)
KR (1) KR102407019B1 (cg-RX-API-DMAC7.html)
CN (1) CN107073099B (cg-RX-API-DMAC7.html)
AU (2) AU2015222685A1 (cg-RX-API-DMAC7.html)
CA (1) CA2940570A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201607130RA (cg-RX-API-DMAC7.html)
WO (1) WO2015127501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
EP3110443A4 (en) * 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
EP3362091A4 (en) * 2015-10-15 2019-04-24 Duke University COMBINATION THERAPY
RU2021114137A (ru) 2016-01-27 2021-05-25 Онкорус, Инк. Онколитические вирусные векторы и их применение
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018185307A1 (en) * 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11230189B2 (en) 2019-03-29 2022-01-25 Honda Motor Co., Ltd. System and method for application interaction on an elongated display screen
MX2022007679A (es) 2019-12-20 2022-07-19 Merck Sharp & Dohme Llc Composiciones purificadas de enterovirus y metodos de purificacion por cromatografia de afinidad con glutation.

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DE69435155D1 (de) 1993-04-30 2008-12-04 Wellstat Biologics Corp Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US6190901B1 (en) 1995-10-17 2001-02-20 Wayne State University Chicken interleukin-15 and uses thereof
JP4413999B2 (ja) 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
KR20000048628A (ko) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
WO1999015672A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU9603898A (en) 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1086207B1 (en) 1998-06-12 2007-01-17 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
EP1390046A4 (en) 1999-04-15 2005-04-20 Wellstat Biologics Corp TREATMENT OF NEOPLASMS WITH VIRUSES
AU4971500A (en) 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
DE60043547D1 (de) 1999-09-24 2010-01-28 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ATE305801T1 (de) 2000-01-20 2005-10-15 Univ Zuerich Inst Fuer Medizin Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
WO2002102404A1 (en) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Uses of cytokines
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2003102183A1 (en) 2002-06-03 2003-12-11 Dnavec Research Inc. Pramyxovirus vectors encoding antibody and utilization thereof
AU2003250575A1 (en) 2002-08-07 2004-02-25 Mmagix Technology Limited Apparatus, method and system for a synchronicity independent, resource delegating, power and instruction optimizing processor
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
ZA200608222B (en) 2004-03-11 2008-07-30 Viralytics Ltd Modified oncolytic viruses
US8236298B2 (en) * 2004-08-20 2012-08-07 Viralytics Limited Methods and compositions for treatment of hematologic cancers
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
AU2005303912B2 (en) 2004-11-12 2011-02-17 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
CN102166218A (zh) 2005-01-17 2011-08-31 溶瘤病毒有限公司 治疗肿瘤的方法和组合物
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
WO2007008918A2 (en) 2005-07-08 2007-01-18 Wayne State University Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
CA2825762A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
CA2658584A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
NZ616254A (en) 2007-06-27 2015-04-24 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
JP6221167B2 (ja) 2009-08-21 2017-11-01 メリアル インコーポレイテッド 組換えトリパラミクソウイルスワクチン並びに前記の製造および使用方法
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2012000188A1 (en) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
ES2651170T3 (es) 2010-09-21 2018-01-24 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
CN104093830A (zh) 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013053775A1 (en) 2011-10-11 2013-04-18 Universität Zürich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
ES2906615T3 (es) 2013-04-19 2022-04-19 Cytune Pharma Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
CA2915397A1 (en) 2013-06-17 2014-12-24 Viralytics Limited Methods for the treatment of bladder cancer
HUE046964T2 (hu) 2013-08-08 2020-04-28 Cytune Pharma Kombinált gyógyászati készítmény
MX374291B (es) 2013-08-08 2025-03-06 Cytune Pharma Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
WO2015032755A1 (en) 2013-09-03 2015-03-12 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
EP3110443A4 (en) * 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP3174974B1 (en) 2014-07-29 2020-05-20 Novartis AG Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016048903A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
CA2968406A1 (en) 2014-12-09 2016-06-16 Mark D. Ayers System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技(北京)有限公司 一种用于术前介入放疗治疗肿瘤的化合物
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用

Similar Documents

Publication Publication Date Title
JP2017506662A5 (cg-RX-API-DMAC7.html)
Morris et al. Interaction of radiation therapy with molecular targeted agents
JP2021063120A5 (cg-RX-API-DMAC7.html)
Perry et al. Novel therapies in glioblastoma
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
Liu et al. Effects of oncolytic viruses and viral vectors on immunity in glioblastoma
Middleton et al. Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors
JP7307044B2 (ja) 逐次的抗癌治療
Chen et al. Overview of tumor immunotherapy based on approved drugs
Portnow et al. Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients
RU2016108809A (ru) Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба
Eshun et al. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
JP2018501247A5 (cg-RX-API-DMAC7.html)
Young et al. Ideal timing of immunotherapy with radiation in murine tumor models
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
Liu et al. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma
Kleinovink et al. Combination of Photodynamic Therapy and Immune Checkpoint Blockade
Wang et al. Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1/CD3 bispecific antibody
CN102363780A (zh) 靶向人cd147小分子rna干扰序列及其用途
Castro et al. EXTH-52. HARNESSING AB CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE
Tosin et al. EXTH-48. INHIBITION OF SREBP-1 IS SYNTHETICALLY LETHAL WITH BCL-XL/BCL-2 INHIBITION IN GLIOBLASTOMA IN VITRO
Seddiq Engineered Stem Cells Releasing Oncolytic Virus and Immunomodulators Have Therapeutic Efficacy in Brain Metastatic Tumors
Sardi et al. Drug penetration through the blood–brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance
Roxburgh et al. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer
Jung et al. CSIG-34. PDGFRb SIGNALING MAINTAINS GLIOBLASTOMA SURVIVAL VIA HYPOXIA-INDUCED MITOPHAGY